Infliximab en el tratamiento de la enfermedad de Crohn: Estudio preliminar / Infliximab in the treatment of patients with Crohn's disease: Preliminary report
Rev. méd. Chile
;
134(3): 320-325, mar. 2006. tab, graf
Article
in Spanish
| LILACS
| ID: lil-426098
ABSTRACT
Background:
Tumor necrosis factor alpha, interleukin 6 and 1 have a pathogenic role in Crohn's disease. Infliximab, a monoclonal antibody against tumor necrosis factor, is useful in the treatment of Crohn's disease, specially when the disease is active and associated to fistula formation.Aim:
To assess the effectiveness of Infliximab in patients with Crohn's disease. Material andmethods:
Twelve patients with Crohn's disease (aged 16 to 63 years, 10 women) refractory to treatment with steroid, 5-aminosalicylic acid, antimicrobials and immunomodulatory drugs, were studied. A single intravenous 5 mg/kg dose Infliximab was administered. The Crohn's disease activity index (CDAI) was measured before and one week after the administration of the drug.Results:
CDAI before and after Infliximab administration was 357±62 and 138±122 score points, respectively (p <0.005). According to this score, five patients had a severe and seven a moderate disease flare. The disease remitted in 7 (58%) and a clinical response was observed in 75%.Conclusions:
A single dose of Infliximab was effective to induce remission of the disease in 75% of this selected group of patients with Crohn's disease.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Gastrointestinal Agents
/
Crohn Disease
/
Antibodies, Monoclonal
Type of study:
Observational study
/
Risk factors
Limits:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
Language:
Spanish
Journal:
Rev. méd. Chile
Journal subject:
Medicine
Year:
2006
Type:
Article
Affiliation country:
Chile
Institution/Affiliation country:
Clínica las Condes/CL
/
Corporación Nacional del Cobre de Chile/CL
/
Pontificia Universidad Católica de Chile/CL
/
Universidad de Chile/CL
/
Universidad de Los Andes/CL
Similar
MEDLINE
...
LILACS
LIS